BriaCell Therapeutics (TSX:BCT) Accounts Payable : C$4.98 Mil (As of Jan. 2024)

View and export this data going back to 2006. Start your Free Trial

What is BriaCell Therapeutics Accounts Payable?

BriaCell Therapeutics's Accounts Payable for the quarter that ended in Jan. 2024 was C$4.98 Mil.

BriaCell Therapeutics's quarterly Accounts Payable declined from Jul. 2023 (C$1.49 Mil) to Oct. 2023 (C$0.60 Mil) but then increased from Oct. 2023 (C$0.60 Mil) to Jan. 2024 (C$4.98 Mil).

BriaCell Therapeutics's annual Accounts Payable increased from Jul. 2021 (C$0.27 Mil) to Jul. 2022 (C$0.60 Mil) and increased from Jul. 2022 (C$0.60 Mil) to Jul. 2023 (C$1.49 Mil).

BriaCell Therapeutics Accounts Payable Historical Data

The historical data trend for BriaCell Therapeutics's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BriaCell Therapeutics Accounts Payable Chart

BriaCell Therapeutics Annual Data

Trend

Jul14

Jul15

Jul16

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

Jul23

Accounts Payable

Get a 7-Day Free Trial

0.27

0.60

1.49

BriaCell Therapeutics Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Accounts Payable	Get a 7-Day Free Trial															0.78	1.34	1.49	0.60	4.98

BriaCell Therapeutics Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

BriaCell Therapeutics Accounts Payable Related Terms

Thank you for viewing the detailed overview of BriaCell Therapeutics's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

BriaCell Therapeutics (TSX:BCT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BriaCell Therapeutics Corp (TSX:BCT) » Definitions » Accounts Payable

Comparable Companies

Traded in Other Exchanges

BCTX:USA

Address

235 - 15th Street, Suite 300, West Vancouver, 3rd Floor, Bellevue Centre, Vancouver, BC, CAN, V7T 2X1

Website

https://www.briacell.com

BriaCell Therapeutics Corp is an immuno-oncology-focused biotechnology company. The group develops targeted and safe approaches for the management of cancer. BriaCell is conducting a Phase I/IIa clinical trial of Bria-IMT in metastatic breast cancer. Additionally, it is developing Bria-OTS, off-the-shelf personalized immunotherapy, for the treatment of advance-stage breast cancer by matching the patient's HLA type.

Executives

Jamieson Bondarenko

Director

BriaCell Therapeutics (TSX:BCT) Headlines

No Headlines